Peg-IFN-alfa-2b/Ribavirin combination therapy for chronic hepatitis C patients: Effectiveness prediction by gene analysis and efficacy with Fluvastatin combination

Peg-IFN-alfa-2b/Ribavirin combination therapy for chronic hepatitis C patients: Effectiveness prediction by gene analysis and efficacy with Fluvastatin combination - Effectiveness prediction for Peg-IFN-alfa-2b/Ribavirin combination therapy for chronic hepatitis C and efficacy with Fluvastatin combination

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000008196

Enrollment

200

Registered

2012-06-19

Start date

2010-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic hepatitis C

Interventions

IL-28B SNP major type: 48 or 72 week Peg-IFN-alfa-2b/Ribavirin combination thrapy depend on viral response. IL-28B SNP minor type: 48 or 72 week Peg-IFN-alfa-2b/Ribavirin combination thrapy add on Flu

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: chronic hepatitis C serogroup1, high viral load

Exclusion criteria

Exclusion criteria: contraindication of Peg-IFN/Ribavirin thrapy

Design outcomes

Primary

Measure	Time frame
Efficacy	—

Countries

Japan

Contacts

Public ContactTetsuro Shimakami

Kanazawa University University hospital

shimakami@m-kanazawa.jp076-265-2235

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026